A Common Point of Confusion
AOD 9604 and HGH Fragment 176-191 are frequently confused or treated as interchangeable in peptide research discussions. While they share the same amino acid sequence from positions 176-191 of human growth hormone, there is a critical structural difference that affects their biological activity.
The Key Difference: C-Terminal Tyrosine
AOD 9604 includes a specific tyrosine modification at the C-terminus of the hGH 176-191 sequence. This modification enhances the peptide’s stability, receptor binding affinity, and biological activity for lipolysis. HGH Fragment 176-191 is the unmodified sequence without this addition.
Comparison
| Feature | AOD 9604 | HGH Fragment 176-191 |
|---|---|---|
| Sequence | hGH 176-191 + C-terminal Tyr | hGH 176-191 (unmodified) |
| Clinical trials | Phase 2/3 completed | Limited formal trials |
| Stability | Enhanced | Standard |
| GRAS status | Yes (FDA designation) | No |
| Lipolytic potency | Higher (modified) | Baseline |
Mechanism
Both compounds stimulate lipolysis and inhibit lipogenesis in adipose tissue without affecting IGF-1, blood glucose, or growth parameters. The mechanism involves beta-3 adrenergic receptor pathway activation in fat tissue. AOD 9604’s tyrosine modification is thought to enhance receptor interaction and enzymatic stability.
Clinical Evidence
AOD 9604 has the stronger evidence base, having completed Phase 2/3 clinical trials in Australia and received GRAS (Generally Recognized as Safe) designation from the FDA for oral formulations. HGH Fragment 176-191 lacks this level of clinical validation.
Recommendation for Research
For metabolic research requiring rigorous data, AOD 9604 is the preferred compound due to its enhanced stability, clinical trial backing, and regulatory recognition. See our AOD 9604 dosage guide and benefits overview.
For research purposes only. AOD 9604 available. Visit COAs.